CynergisTek Announces Northeast Health System Expands Relationship with Addition of Medical Device Security Services

Northeast health system chooses CynergisTek to assess the organization’s medical device security program and help build out specific policies and procedures unique to securing medical devices

AUSTIN, Texas–(BUSINESS WIRE)–$CTEK #IoMT—CynergisTek (NYSE American: CTEK), a leading cybersecurity, privacy, compliance, and IT audit firm helping organizations in highly regulated industries navigate emerging security and privacy issues, announces a six-figure expansion contract with a large multi-site health system to conduct medical device security assessment and program development services.

Network-connected medical devices are one of the biggest cybersecurity challenges for healthcare organizations since they can often be a potential unwelcome backdoor into their environment and a risk to patient safety and privacy. On average there are 10-15 connected medical devices per bed, multiply that by the number of beds in the U.S. and the threat of these devices materializes quickly. “The problem is that with the proliferation of Internet of Things (IoT), the speed at which new medical devices are introduced into a Healthcare Delivery Organization’s (HDO) network has increased. Both new and legacy devices being used today have introduced vulnerabilities due to outdated or insecure software, poor configurations, location, etc.,” said Mac McMillan, CEO and President at CynergisTek.

CynergisTek’s medical device security team will work with the health system to evaluate the effectiveness of their program for providing ongoing risk management of connected devices and will develop policies and procedures that are unique to medical devices beginning with pre-procurement security reviews, identifying, and prioritizing risk, and updating vulnerabilities with the manufacturer. “Cybersecurity is complex and constantly evolving – there are so many moving parts. With the increase in IoT and the number of ransomware attacks on healthcare organizations, many are bringing in the expertise to help review and improve upon medical device security programs to ensure that they are doing their best to protect patient safety and privacy,” said Dave Bailey, VP of Security Services at CynergisTek.

“Working with our client is a sign of another great partnership, and I would like to give credit to their team and the hospital’s leadership for investing in and making security a priority for their organization – many have not performed this important analysis, but the tide is shifting as more HDOs are understanding the importance of addressing this risk,” said Mac McMillan. He goes onto say, “Working with CynergisTek’s team that combines both cybersecurity and clinical engineering experts helps organizations identify and address network-connected medical device security in a holistic fashion. Compromise of these devices can lead to patient harm or become the jumping off point for disrupting hospital operations and patient care and lead to the losses in revenue in the millions.”

About CynergisTek, Inc.

CynergisTek (www.cynergistek.com), is a top-ranked cybersecurity consulting firm helping organizations in highly-regulated industries, including those in healthcare, government, and finance navigate emerging security and privacy issues. CynergisTek combines intelligence, expertise, and a distinct methodology to validate a company’s security posture and ensure the team is rehearsed, prepared, and resilient against threats. Since 2004, CynergisTek has been dedicated to hiring and retaining experts who bring real-life experience and hold advanced certifications to support and educate the industry by contributing to relevant industry associations. For more information, visit www.cynergistek.com or follow us on Twitter or LinkedIn.

Cautionary Note Regarding Forward Looking Statements

This release contains certain forward-looking statements relating to the business of CynergisTek, Inc. These forward-looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and can be identified by the use of forward-looking terminology such as “believes,” “expects,” “anticipates,” “would,” “could,” “intends,” “may,” “will,” or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including but not limited to uncertainties relating to product/services development; long and uncertain sales cycles; the ability to obtain or maintain proprietary intellectual property protection; future capital requirements; competition from other providers; the ability of the Company’s vendors to continue supplying the Company with supplies and services at comparable terms and prices; the Company’s ability to successfully compete and introduce enhancements and new features that achieve market acceptance and that keep pace with technological developments; the Company’s ability to maintain its brand and reputation and retain or replace its significant customers; cybersecurity risks and risks of damage and interruptions of information technology systems; the Company’s ability to retain key members of management and successfully integrate new executives; the Company’s ability to complete acquisitions, strategic investments, entry into new lines of business, divestitures, mergers or other transactions on acceptable terms, or at all; potential risks and uncertainties relating to the existing and ultimate impact of COVID-19, including the geographic spread, the severity of the virus, the duration of the COVID-19 outbreak, actions that may be taken by governmental authorities to contain the COVID-19 outbreak or to treat its impact, and the potential negative impacts of COVID-19 on the global economy and financial markets, and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in the Company’s Form 10-K and Form 10-Q filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Given the risks and uncertainties, readers should not place undue reliance on any forward-looking statement and should recognize that the statements are predictions of future results which may not occur as anticipated. Many of the risks listed above have been, and may further be, exacerbated by the COVID-19 pandemic, including its impact on the healthcare industry. Actual results could differ materially from those anticipated in the forward-looking statements and from historical results, due to the risks and uncertainties described herein, as well as others not now anticipated. CynergisTek is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.

Contacts

CynergisTek Investor Relations Contact:
CynergisTek, Inc.

Bryan Flynn

(512) 402-8550 x8

InvestorRelations@cynergistek.com

CynergisTek Media Contact:
Allison + Partners

Jaime Tero

415-755-8639

jaime.tero@allisonpr.com